SIGN UPLog In

Last deal

$65M

Amount

Post-IPO Equity

Stage

11.05.2020

Date

7

all rounds

$257.4M

Total amount

General

About Company
Intersect ENT is a medical device company that provides therapy solutions for ENT physicians to improve patients' quality of life..

Industry

Sector :

Subsector :

Also Known As

Sinexus, Sinexus Inc

founded date

01.01.2003

Number of employees

251-500

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Headquartered in Menlo Park, California, United States, Intersect ENT was founded in 2003 by Don Eaton. The company's PROPEL and PROPEL mini drug-releasing implants are used to treat chronic sinusitis, while PROPEL contour is used to treat frontal and maxillary sinus ostia. For more information on the company and its products, including risks and benefits, visit www.intersectENT.com.
Contacts

location

Menlo Park, CA, USA

Phone number

Website URL

http://www.intersectent.com

Social url